SMid Cap Biotech Analyst Rama and Large Cap Biotech Analyst Fye, along with Dr. Wen-Hann Tan, of Boston Children’s Hospital, discusses Angelman Syndrome Development Landscape Assessment (relevant companies RARE, IONS) on an Analyst/Industry conference call to be held on June 6 at 2:30 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
- Ultragenyx price target raised to $83 from $81 at Barclays
- Ultragenyx price target lowered to $76 from $83 at BofA
- Ultragenyx price target raised to $127 from $124 at Stifel
- Ultragenyx price target raised to $115 from $107 at Cantor Fitzgerald
Questions or Comments about the article? Write to editor@tipranks.com